新型口服抗凝药在肝硬化合并门静脉血栓的治疗进展  

Advance of New Oral Anticoagulants in the Treatment of Portal Vein Thrombosis in Cir-rhosis

作　　者：周好男 陈以宽[1] 

机构地区：[1]重庆医科大学附属第二医院血管外科,重庆

出　　处：《临床医学进展》2023年第3期3788-3795,共8页Advances in Clinical Medicine

摘　　要：门静脉血栓(PVT)是肝硬化患者的常见并发症,可合并腹水、凝血功能异常、静脉曲张出血等。目前抗凝治疗作为一线治疗。与传统抗凝药相比,新型口服抗凝药具有起效快、不需要常规监测、食物药物相互作用较少,越来越受到关注。但是新型口服抗凝药用于治疗肝硬化合并PVT的相关研究较少。本文就新型口服抗凝药用于治疗肝硬化合并PVT患者的现有文献进行综述。Portal vein thrombosis (PVT) is a common complication in cirrhotic patients, usually companying with ascites, coagulation abnormalities, and variceal bleeding. Anticoagulation is currently used as first-line therapy. The use of the new oral anticoagulants (NOACs) for the treatment of PVT is raising concerns as they have a rapid onset of action, no requirement for routine coagulation monitoring, and a smaller number of food-drug interactions compared to traditional anticoagulants. However, few studies have discussed the use of NOACs in the treatment of cirrhosis with PVT. The purpose of this review is to evaluate the existing literature on the advance of NOACs in the treatment of cirrho-sis patients with PVT.

关 键 词：肝硬化 门静脉血栓 抗凝治疗 新型口服抗凝药 

分 类 号：R57[医药卫生—消化系统]